文献速递前列腺癌

SelectMDx在前列腺癌诊断中的成本效果:四欧洲国家比较建模研究

Cost-effectiveness of SelectMDx for prostate cancer in four European countries: a comparative modeling study.
PubMed 文献 · Prostate Cancer Prostatic Dis · 2018-08-20

该建模研究评估SelectMDx®在法国、德国、意大利和西班牙用于初始前列腺活检决策的健康获益与成本效果。决策模型比较现行标准(PSA升高即活检)与SelectMDx筛选策略,计算长期QALYs和医疗成本。四国中SelectMDx策略均获得QALY增益并节省成本,主要归因于减少不必要活检及过度治疗。

要点

  • 四国中SelectMDx策略均较现行标准获得QALY增益并节省医疗成本
  • 法国QALY增益0.022、节省€1217/患者;德国0.016、€442;意大利0.031、€762;西班牙0.020、€250
  • 获益主要源于当前标准下过度治疗显著,SelectMDx可减少不必要初始活检

核心结论

  • 在法国、德国、意大利和西班牙,SelectMDx用于前列腺癌初始诊断可获QALY增益并节省医疗成本。

研究设计与样本

  • 决策模型比较现行标准(PSA升高即初始前列腺活检)与SelectMDx筛选活检策略,输入四国最相关模型参数,计算长期QALYs和医疗成本。

主要发现

  • 法国:QALY增益0.022,节省€1217/患者。
  • 德国:QALY增益0.016,节省€442。
  • 意大利:QALY增益0.031,节省€762。
  • 西班牙:QALY增益0.020,节省€250。
  • 四国现行标准下过度治疗显著,是SelectMDx获益的主要因素。

临床怎么用

  • 在四国医疗背景下,可考虑用SelectMDx筛选初始活检对象,以减少不必要活检和过度治疗并节省成本。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Low specificity of prostate-specific antigen results in a considerable number of unnecessary prostate biopsies in current practice. SelectMDx® predicts significant prostate cancer upon biopsy and is used to reduce the number of unnecessary initial prostate biopsies. Furthermore, potential overtreatment of insignificant prostate cancer can be reduced. Besides the diagnostic accuracy of the test, also the context in a specific country determines the potential health benefit and cost-effectiveness. Therefore, the health benefit and cost-effectiveness of SelectMDx were assessed in France, Germany, Italy, and Spain. SUBJECT AND METHODS: A decision model was used to compare the current standard of care in which men undergo initial prostate biopsy in case of an elevated prostate-specific antigen, to a strategy in which SelectMDx was used to select men for biopsy. Model inputs most relevant to each of the four countries were obtained. With use of the model long-term quality-adjusted life years (QALYs) and healthcare costs were calculated for both strategies. RESULTS: In all four countries, the SelectMDx resulted in QALY gain and cost savings compared with the current standard of care. In France, SelectMDx resulted in 0.022 QALYs gained and cost savings of €1217 per patient. For Germany, the model showed a QALY gain of 0.016 and a cost saving of €442. In Italy, the QALY gain and cost savings were 0.031 and €762. In Spain 0.020 QALYs were gained and €250 costs were saved. CONCLUSIONS: The results of the model showed that with SelectMDx, QALYs could be gained while saving healthcare costs in the initial diagnosis of prostate cancer. The significant presence of overtreatment in the current standard of care in all four countries was the main factor that resulted in the beneficial outcomes with SelectMDx.

来源:Prostate Cancer Prostatic Dis,查看原文。版权归原作者所有。

引用

  1. Govers TM, Hessels D, Vlaeminck-Guillem V, et al. Cost-effectiveness of SelectMDx for prostate cancer in four European countries: a comparative modeling study. Prostate Cancer Prostatic Dis. 2018. PMID: 30127462. doi:10.1038/s41391-018-0076-3

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。